Mitochondrial‐Targeting Vitamin B ₃ Ameliorates the Phenotypes of Parkinson's Disease in vitro and in vivo by Restoring Mitochondrial Function

Chenqi Xin,Naidi Yang,Yaqi Ding,Linqi Han,Zhiqiang Zhou,Xiaolu Guo,Zhijie Fang,Hua Bai,Bo Peng,Chengwu Zhang,Lin Li

DOI: https://doi.org/10.1002/adtp.202200094

IF: 5.003

2022-01-01

Advanced Therapeutics

Abstract:Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by progressive dopaminergic neuron loss, which affects millions of people worldwide, especially elderly individuals. Mitochondrial dysfunction is believed to be one crucial causative factor of PD. Therefore, restoring mitochondrial function is highly recommended for the treatment of PD. Herein, it is found that vitamin B-3 (VB3) protects the dopaminergic cell line SH-SY5Y against rotenone-induced apoptosis by restoring mitochondrial dysfunction. To further improve the efficacy, a derivative of VB3, mitochondrial-targeting VB3 (Mito-VB3), is developed. It is demonstrated that Mito-VB3 rescues SH-SY5Y cells from the neurotoxicity of oxidative stress. More importantly, Mito-VB3 ameliorates the phenotypes of the Drosophila PD model. Mechanistically, Mito-VB3 enhances nicotinamide adenine dinucleotide (NAD(+)) levels, reduces ROS generation, elevates ATP levels, and restores mitochondrial membrane potential. Meanwhile, Mito-VB3 promotes mitochondrial biogenesis by activating the NAD(+)/SIRT1/PGC1 alpha pathway. In summary, the results demonstrate that Mito-VB3 displays remarkable neuroprotective effects in the cell and Drosophila PD models and that Mito-VB3 might serve as a potential therapeutic candidate for the treatment of PD and other mitochondrial dysfunction-related diseases.